Thomas Buchholz
Direktor/Vorstandsmitglied bei Nucleix Ltd.
Aktive Positionen von Thomas Buchholz
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Nucleix Ltd.
 Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Direktor/Vorstandsmitglied | 11.05.2020 | - |
Karriereverlauf von Thomas Buchholz
Ausbildung von Thomas Buchholz
| Tufts University School of Medicine | Doctorate Degree |
| Bucknell University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Israel | 2 |
Operativ
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
| Director/Board Member | 1 |
Sektoral
| Consumer Services | 3 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Nucleix Ltd.
Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Health Services |
- Börse
- Insiders
- Thomas Buchholz
- Erfahrung
